Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review

被引：0
作者：
Marko Barešić
Ljiljana Smiljanić Tomičević
Branimir Anić
Miroslav Mayer
机构：
[1] University of Zagreb,Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University Hospital Center Zagreb
来源：
Rheumatology International | 2022年 / 42卷
关键词：
Psoriatic arthritis; Interleukin-17A inhibitor; Cycling; Secukinumab; Ixekizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Psoriatic arthritis is an inflammatory arthritis with heterogeneous disease presentation. The most affected clinical domain of the disease determines the therapeutic approach. We report the case of a 34-year-old man with all six crucial domains of psoriatic arthritis (psoriasis, peripheral arthritis, axial skeletal manifestations, dactylitis, nail changes, and enthesitis) treated unsuccessfully with conventional synthetic DMARDs, NSAID’s, and steroids as well as topical treatment and phototherapy. With golimumab as the first line of bDMARD partial remission was achieved. After 24 months the treatment was switched to secukinumab due to secondary inefficacy. The psoriasis and psoriatic arthritis relapsed after 21 months of treatment with secukinumab. The patient was cycled to ixekizumab with an excellent result. IL-17A inhibitor cycling may be a successful treatment option in some difficult to treat psoriatic arthritis patients.
引用
收藏
页码：365 / 370
页数：5
相关论文
共 134 条
  • [1] Gladman DD(2005)Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 ii14-17
  • [2] Antoni C(2006)Classification criteria for psoriatic arthritis: development of new criteria from a large international study Arthritis Rheum 54 2665-2673
  • [3] Mease P(2016)Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis Arthritis Rheumatol 68 1060-1071
  • [4] Clegg DO(2020)EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update Ann Rheum Dis 79 700-712
  • [5] Nash P(2020)Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study ACR Open Rheumatol 2 18-25
  • [6] Taylor W(2019)Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study J Eur Acad Dermatol Venereol 33 e7-8
  • [7] Gladman D(2019)No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis J Dermatol Treat 30 216-220
  • [8] Helliwell P(2020)Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab Dermatol Online J 26 13030-851
  • [9] Marchesoni A(2007)Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue Ann Rheum Dis 66 849-3319
  • [10] Mease P(2003)Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade Arthritis Rheum 48 3308-192
12345678910